---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-311957"
form_type: "8-K"
ticker: "VOR"
cik: "0001817229"
company_name: "Vor Biopharma Inc."
filed_at: "2025-12-09T23:59:59+00:00"
generated_at: "2026-05-16T13:49:49.923336+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vor Biopharma reprices employee stock options to $8.18; CEO gets 4.16M options repriced

## Summary
- Board reduced exercise price of ~5.2M underwater options to $8.18, the Dec 5, 2025 closing price.
- Repriced options originally ranged from $17.80 to $47.60; CEO Jean-Paul Kress repriced 4,164,831 options.
- Retention period ends Dec 5, 2027; options exercised earlier retain original exercise price.
- CFO Sandy Mahatme received option for 1,388,274 shares at $17.80, reducing to $8.18 after retention period.
- Repricing aims to retain employees and avoid dilution from new equity grants or cash comp.

## SEC filing metadata
- accession: 0001193125-25-311957
- form_type: 8-K
- ticker: VOR
- cik: 0001817229
- company_name: Vor Biopharma Inc.
- filed_at: 2025-12-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817229/000119312525311957/0001193125-25-311957-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817229/000119312525311957/vor-20251205.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-311957
- JSON: https://secwatch.observer/filing/0001193125-25-311957.json
- Plain text: https://secwatch.observer/filing/0001193125-25-311957.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.